{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=35&state=Michigan", "query": { "state": "Michigan", "city": "Detroit", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 7238, "total_pages": 724, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=36&state=Michigan&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=34&state=Michigan&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T02:46:22.214Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01404312", "title": "Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberculosis", "HIV Infections" ], "interventions": [ { "name": "Rifapentine (RPT)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Pyridoxine (Vitamin B6)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 3000, "start_date": "2012-05-23", "completion_date": "2017-11-14", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-11-03T02:46:22.214Z", "location_count": 21, "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01404312" }, { "nct_id": "NCT01964430", "title": "Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the \"Apact\" Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Neoplasms", "Digestive System Neoplasms", "Neoplasms by Site", "Neoplasms", "Endocrine Gland Neoplasms", "Pancreatic Diseases", "Digestive System Diseases", "Endocrine System Diseases", "Gemcitabine", "Antimetabolites, Antineoplastic" ], "interventions": [ { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 866, "start_date": "2014-03-28", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-11-03T02:46:22.214Z", "location_count": 107, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01964430" }, { "nct_id": "NCT00604175", "title": "Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Sexually Transmitted Diseases" ], "interventions": [ { "name": "Quadrivalent HPV vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "13 Years to 45 Years · Female only" }, "enrollment_count": 319, "start_date": "2008-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-11-03T02:46:22.214Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Alhambra", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00604175" }, { "nct_id": "NCT00002907", "title": "Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-01", "completion_date": "2000-11", "has_results": false, "last_update_posted_date": "2013-04-05", "last_synced_at": "2026-11-03T02:46:22.214Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002907" }, { "nct_id": "NCT00111631", "title": "A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus Type 2" ], "interventions": [ { "name": "DPP-IV Inhibitor", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 218, "start_date": "2005-05", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-11-03T02:46:22.214Z", "location_count": 20, "location_summary": "Concord, California • Salinas, California • San Diego, California + 17 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00111631" }, { "nct_id": "NCT06072131", "title": "To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "Belinostat Injection", "type": "DRUG" }, { "name": "Pralatrexate Injection", "type": "DRUG" }, { "name": "CHOP", "type": "DRUG" }, { "name": "COP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acrotech Biopharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 504, "start_date": "2023-10-04", "completion_date": "2030-11", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-03T02:46:22.214Z", "location_count": 10, "location_summary": "Clovis, California • Santa Monica, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072131" }, { "nct_id": "NCT04097145", "title": "Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tricuspid Regurgitation", "Tricuspid Valve Insufficiency", "Tricuspid Valve Disease" ], "interventions": [ { "name": "Edwards PASCAL System", "type": "DEVICE" }, { "name": "Optimal Medical Therapy", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Edwards Lifesciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1270, "start_date": "2019-12-11", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-03T02:46:22.214Z", "location_count": 73, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Irvine, California + 59 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04097145" }, { "nct_id": "NCT05410145", "title": "A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS P.G12C" ], "interventions": [ { "name": "D3S-001", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "D3 Bio (Wuxi) Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 442, "start_date": "2022-08-03", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-03T02:46:22.214Z", "location_count": 7, "location_summary": "Orange, California • Palo Alto, California • Denver, Colorado + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05410145" }, { "nct_id": "NCT01598831", "title": "Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Sepsis", "Coagulopathy" ], "interventions": [ { "name": "ART-123", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asahi Kasei Pharma America Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 816, "start_date": "2012-10-29", "completion_date": "2019-02-28", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-11-03T02:46:22.214Z", "location_count": 22, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Atlanta, Georgia + 17 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01598831" }, { "nct_id": "NCT02167945", "title": "A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus (HCV) Infection Genotype 1" ], "interventions": [ { "name": "ABT-450/r/ABT-267", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 615, "start_date": "2014-06-12", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-11-03T02:46:22.214Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02167945" } ] }